Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

This page isn’t intended for discussions about products.  As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. 

Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: 
https://www.novonordisk.com/contact-us/find-local-information.html

For other customer complaints, please contact us here: 
https://www.novonordisk.com/contact-us.html

Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. 

Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.

Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Affimed

Xencor

Innate Pharma

IO Biotech

Pieris Pharmaceuticals

Novo Nordisk

Our full-year results are out!

In 2023, we reached more than 40 million people with our diabetes and obesity medicines.
 
Hear our CEO Lars Fruergaard Jørgensen reflect on our performance and learn more about our results and ambitions in our Annual Report here https://lnkd.in/gu4MH2U
 
 
#DrivingChange #FullYearResults #AnnualReport

We're looking forward to the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 6-9 March! Follow along via Novo Nordisk CongressHub where we'll be highlighting the latest innovations in diabetes care 💙 

https://lnkd.in/g9SWahkq

#ATTD2024 #Diabetes #DiabetesTechnology #Innovation

From small beginnings to groundbreaking innovation - 100 years of #DrivingChange 💙

Learn more about our history of innovation here: https://lnkd.in/dPymS-V5

#NovoNordisk #Heritage #Innovation

How do we contribute to society?
 
Learn more about our commitment to patients, innovation and access to healthcare in our #AnnualReport https://lnkd.in/dxSA_D4V

Inspiring the future of science 💙 
 
From aspiring scientists to our very own colleagues – we’re marking International Day of Women and Girls in Science together.
 
Let’s inspire even more women to a life in science, technology, engineering and math (STEM).
 
Explore our career opportunities here: https://lnkd.in/dfHdaYP
 
#DrivingChange #WomenInScience #STEM

Dr Ulla Hedner - an inspiring pioneer in haemophilia treatment!
 
When Dr Ulla Hedner needed a development partner to produce and test recombinant FVIIa, she turned to us. We were honoured to collaborate on the project in 1985 which has since helped thousands of people living with haemophilia with inhibitors and other rare bleeding disorders.
 
Join us in congratulating her for receiving the 2024 #EAHAD Lifetime Achievement Award for her remarkable contributions to the #haemophilia community in Europe and around the world.
 
#DrivingChange #WomeninScience #Innovation #EAHADCongress

2023 was an extraordinary year of innovation, growth and impact. 
 
Thank you to everyone for #DrivingChange with us!
 
Check out some of our 2023 highlights and learn more in our #AnnualReport here https://lnkd.in/dxSA_D4V

Applications to the Pharmaceutical Medicine Programme (PMP) are now open. This is an exciting opportunity for Medical Doctors with 2-5 years of clinical and/or research experience, to join one of the most successful pharmaceutical companies in the world. Use your medical and scientific expertise to create better treatments and care for people living with serious chronic diseases around the world.

Interested? Find out more about the PMP here: https://brnw.ch/21wGCeB

Pharmaceutical manufacturing has changed dramatically over the last 100 years, making it safer and more efficient than ever before. 

100 years ago, we used manual processes to meet the needs of patients who lived with diabetes in Denmark and in Europe. Today, we produce half of the world’s insulin, and we want to continue to deliver the highest quality of care to patients for generations to come. 

To continue meeting the needs of our millions of patients around the globe, we’re ramping up our production – fast. But scaling at speed demands doing things differently. Thinking outside of the box. To get there, we’re embracing modern technology and bringing the best minds together. This is where you come in! Help us ramp up our production while you ramp up your career!  Visit: https://brnw.ch/21wGpy6

Obesity can have many different causes, and can lead to multiple chronic health issues.

We are #drivingchange to make #obesity a healthcare priority.

Learn more here: https://lnkd.in/eCyWpsQ

NYSE:NVO

Novo Nordisk A/S

Last Close

126.16

25/04 20:00

Market Cap

477.03B

Beta: 0.31

Volume Today

3.39M

Avg: 1.35M

PE Ratio

43.81

PFCF: 52.23

Dividend Yield

0.25%

Payout:37.96%

Share Trends

Transaction Log

Please Sign In To Use The Chat